诚意药业 (603811.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

9.6x

Market Cap

CNY 3.32B

MomentumView details →

1D Return

−2.16%

YTD Return

−31.33%

RSI (14)

42.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

9.6x

Market Cap

CNY 3.32B

RSI (14)

42.1

MomentumView details →

1D Return

−2.16%

YTD Return

−31.33%

ProfitabilityView details →

Gross Margin

70.02%

Net Margin

23.39%

EBITDA Margin

38.60%

ROE (TTM)

13.35%

ROA (TTM)

10.87%

Asset Turnover

0.48x

GrowthView details →

Revenue YoY

+10.82%

EPS YoY

−6.76%

FCF YoY

+1.55%

Revenue CAGR 3Y

+7.44%

EPS CAGR 3Y

+7.57%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

1.74x

Quick Ratio

1.31x

Div Yield

5.83%

Div Rate

CNY 0.42

Div Growth 1Y

+68.00%

Financials snapshotView financials →

Revenue (TTM)

827.75M

Net Income (TTM)

193.61M

Op. CF (TTM)

279.11M

Latest newsMore news →

Chengyi Pharmaceutical announced its first-half 2026 results: revenue of 432 million yuan, up 3.63% year-on-year, and net profit attributable to shareholders of 94.8687 million yuan, down 15.61% year-on-year.10d ago

Similar companies

Atai Beckley N.VATAI 国发股份600538.SH 健之佳605266.SH Shanghai Pioneer Holding Ltd01345.HK 亚宝药业600351.SH 第一医药600833.SH Find similar companies →

Latest newsMore news →

Chengyi Pharmaceutical announced its first-half 2026 results: revenue of 432 million yuan, up 3.63% year-on-year, and net profit attributable to shareholders of 94.8687 million yuan, down 15.61% year-on-year.10d ago